Refine Search

Search Results -

Terms	Documents
L5 and L8	26

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L14

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Wednesday, February 02, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT; PLUR=YES; OP=AND			
L14	l5 and l8	26	L14
L13	l5 with l8	0	L13
L12	l1 and l10	24	L12
L11	l1 and l10L10	0	L11
L10	l8 near3 l3	1430	L10
L9	L8 near5 l3	2020	L9
L8	carbohydrate or polysaccharide or lipid or glycolipid or carrier adj conjugate or lipopolisaccharide or phage or bacteria	246310	L8
L7	l2 and l5	26	L7
L6	l5 and l2L5	0	L6
L5	l1 near8 l3	26	L5
L4	l1 and L3	251	L4
L3	immune adj response	42301	L3

h e b b cg b e e ch

L2	carbohydrate polysaccharide or lipid or glycolipid or carrier adj conjugate or lipopolisaccharide or phage or bacteria	202622	L2
L1	(polynucleotide or dna or cdna or nucleic adj acid) near6 il-12	268	L1

END OF SEARCH HISTORY

h e b b cg b e e ch

Generate Collection | Print

Search Results - Record(s) 1 through 20 of 24 returned.

☐ 1. 20040247662. 17 Feb 04. 09 Dec 04. Systemic immune activation method using nucleic acid-lipid complexes. Dow, Steven W., et al. 424/450; 435/458 514/44 A61K048/00 A61K009/127 C12N015/88.

☐ 2. 20040219096. 18 Dec 03. 04 Nov 04. Uses of mammalian cytokine; related reagents. De Waal Malefyt, Rene, et al. 424/1.41; 435/335 530/389.2 C07K016/00.

☐ 3. 20040186067. 26 Sep 01. 23 Sep 04. Vectors and methods for immunization or therapeutic protocols. Krieg, Arthur M., et al. 514/44; 435/320.1 435/456 435/6 435/91.2 A61K048/00 C12Q001/68 C12N015/86 C12P019/34.

☐ 4. 20040157791. 05 Feb 04. 12 Aug 04. Systemic immune activation method using nucleic acid-lipid complexes. Dow, Steven W., et al. 514/44; 424/450 A61K048/00 A61K009/127.

☐ 5. 20040105866. 04 Nov 03. 03 Jun 04. Pneumococcal and meningococcal vaccines formulated with interleukin-12. LaPosta, Vincent J., et al. 424/184.1; C12Q001/68 A61K039/00 A61K039/38.

☐ 6. 20030180320. 18 Oct 99. 25 Sep 03. ATTENUATED SALMONELLA STRAIN USED AS A VEHICLE FOR ORAL IMMUNIZATION. DARJI, AYUB, et al. 424/200.1; 424/258.1 435/252.3 A61K039/112 C12N001/21.

☐ 7. 20020169285. 20 Nov 01. 14 Nov 02. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis. Reed, Steven G., et al. 530/350; C07K001/00 C07K014/00 C07K017/00.

☐ 8. 20020082297. 02 May 01. 27 Jun 02. Composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease. Verschoor, Jan Adrianus, et al. 514/557; 514/552 554/175 A61K031/23 A61K031/20 C07C051/43.

☐ 9. 20020082296. 02 May 01. 27 Jun 02. A METHOD FOR TREATING AN IMMUNE DISORDER WITH A PURIFIED MYCOBACTERIAL MYCOLIC ACID. Verschoor, Jan Adrianus, et al. 514/557; 514/552 554/175 A61K031/23 A61K031/20 C07C051/43.

☐ 10. 20020081320. 04 Jun 01. 27 Jun 02. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis. Reed, Steven G., et al. 424/269.1; 435/183 435/252.33 435/325 514/44 A61K039/008 A61K048/00 C12N009/00 C12N001/21 C12N005/06.

☐ 11. 20010033839. 16 Apr 01. 25 Oct 01. Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation. Barbera-Guillem, Emilio. 424/130.1; 424/184.1 A61K039/395 A61K039/00.

☐ 12. 6841160. 04 Nov 03; 11 Jan 05. Meningococcal vaccines formulated with interleukin-12. LaPosta; Vincent J., et al. 424/250.1; 424/184.1 424/193.1 424/195.11 424/198.1 424/236.1 424/238.1 424/85.2 514/12 514/2 514/54 514/8 514/885. A61K039/095.

☐ 13. 6821957. 26 Sep 01; 23 Nov 04. Vectors and methods for immunization or therapeutic

h e b b g e e e f e e e e b hh che

protocols. Krieg; Arthur M., et al. 514/44; 424/93.2 435/320.1 435/455 435/91.4. A61K048/00.

☑ 14. 6709658. 10 Feb 99; 23 Mar 04. Pneumococcal vaccines formulated with interleukin-12. LaPosta; Vincent J., et al. 424/195.11; 424/184.1 424/193.1 424/198.1 424/244.1 424/85.2 514/12 514/2 514/54 514/8 514/885. A61K039/385.

☐ 15. 6693086. 25 Jun 98; 17 Feb 04. Systemic immune activation method using nucleic acid-lipid complexes. Dow; Steven W., et al. 514/44; 424/450 435/320.1 435/455 536/23.1. A61K048/00 A61K009/127 C12N015/63 C12N015/87 C07H021/04.

☐ 16. 6638517. 04 Jun 01; 28 Oct 03. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis. Reed; Steven G., et al. 424/269.1; 424/184.1 424/191.1 424/192.1 424/265.1 424/450 424/85.2 435/69.7 514/12 514/2 514/44 530/300 530/350 536/23.1 536/23.4. A61K039/008 A61K039/00 A61K039/002 A61K038/00 A61K045/00.

☐ 17. 6613337. 14 Aug 00; 02 Sep 03. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis. Reed; Steven G., et al. 424/269.1; 424/185.1 424/186.1 424/191.1 424/192.1 424/265.1 424/85.2 435/69.7 514/12 514/2 514/44 530/300 530/350 536/23.1 536/23.4. A61K039/008 A61K039/00 A61K038/00 A61K039/002 A61K045/00.

☑ 18. 6607731. 05 May 00; 19 Aug 03. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis. Reed; Steven G., et al. 424/269.1; 424/184.1 424/185.1 424/191.1 424/192.1 424/265.1 514/12 514/2 514/46 530/300 530/350 536/23.1 536/23.4. A61K039/008 A61K039/00 A61K038/00 A61K039/002 A61K065/00.

☐ 19. 6586409. 24 Mar 00; 01 Jul 03. Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines. Wheeler; Carl J.. 514/44; 424/450 435/320.1 435/455 530/323 560/155 560/224 560/252. A61K048/00 C12N005/00 C12N005/15 C07C069/52 C07C067/02.

☐ 20. 6552006. 30 Jan 01; 22 Apr 03. Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen. Raz; Eyal, et al. 514/44; 435/320.1 536/23.1. A61P037/06.

Generate Collection Print

Terms	Documents
L1 and L10	24

Prev Page Next Page Go to Doc#

h e b b g e e e f e e e e b hh che

Generate Collection | Print

Search Results - Record(s) 21 through 24 of 24 returned.

☐ 21. 6500437. 14 Apr 00; 31 Dec 02. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis. Reed; Steven G., et al. 424/269.1; 424/184.1 424/191.1 424/192.1 424/265.1 424/85.2 435/69.7 514/12 514/2 514/44 530/300 530/350 536/23.1 536/23.4. A61K039/008 A61K039/00 A61K038/00 A61K039/002 A61K045/00.

☐ 22. 6433013. 02 Sep 99; 13 Aug 02. Composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease. Verschoor; Jan Adrianus, et al. 514/557; 514/924. A61K031/19.

☑ 23. 6365165. 30 Oct 98; 02 Apr 02. Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis. Reed; Steven G., et al. 424/269.1; 424/184.1 424/265.1 424/450 424/85.2 514/12 514/2 514/44. A61K039/008 A61K039/00 A61K045/00 A61K038/00 A61K039/002.

☐ 24. 6339068. 20 May 98; 15 Jan 02. Vectors and methods for immunization or therapeutic protocols. Krieg; Arthur M., et al. 514/44; 424/93.2 435/320.1 435/455 435/91.4 435/91.41 435/91.42. A61K048/00 C12N015/00 C12N015/88.

Generate Collection | Print

Terms	Documents
L1 and L10	24

Prev Page Next Page Go to Doc#

h e b b cg b cc e

Generate Collection | Print

Search Results - Record(s) 1 through 20 of 26 returned.

☐ 1. 20040266719. 09 Jul 04. 30 Dec 04. Methods and products for inducing mucosal immunity. McCluskie, Michael J., et al. 514/44; 424/450 A61K048/00 A61K009/127.

☐ 2. 20040198680. 03 Jul 03. 07 Oct 04. Nucleic acid compositions for stimulating immune responses. Krieg, Arthur M.. 514/44; 424/184.1 424/186.1 424/190.1 424/85.1 A61K048/00 A61K039/00 A61K039/38 A61K039/12 A61K038/19.

☐ 3. 20040186067. 26 Sep 01. 23 Sep 04. Vectors and methods for immunization or therapeutic protocols. Krieg, Arthur M., et al. 514/44; 435/320.1 435/456 435/6 435/91.2 A61K048/00 C12Q001/68 C12N015/86 C12P019/34.

☐ 4. 20040152649. 03 Jul 03. 05 Aug 04. Nucleic acid compositions for stimulating immune responses. Krieg, Arthur M.. 514/44; 424/85.1 A61K048/00 A61K038/19.

☐ 5. 20040096462. 23 Jun 03. 20 May 04. Noval vaccine formulation consisting of dna vaccine and inactivated virus. Rangarajan, Pundi Narasimhan, et al. 424/204.1; 424/224.1 A61K039/12 A61K039/205.

☐ 6. 20040092472. 03 Jul 03. 13 May 04. Nucleic acid compositions for stimulating immune responses. Krieg, Arthur M.. 514/44; 424/185.1 424/186.1 424/190.1 424/191.1 424/85.1 A61K048/00 A61K038/19 A61K039/00 A61K039/12 A61K039/02 A61K039/002.

☐ 7. 20040067905. 03 Jul 03. 08 Apr 04. Nucleic acid compositions for stimulating immune responses. Krieg, Arthur M.. 514/44; 424/185.1 424/85.1 A61K048/00 A61K038/19 A61K039/00.

☐ 8. 20040053880. 03 Jul 03. 18 Mar 04. Nucleic acid compositions for stimulating immune responses. Krieg, Arthur M.. 514/44; 424/186.1 424/190.1 424/191.1 424/85.1 A61K048/00 A61K039/12 A61K039/02 A61K039/002 A61K038/19.

☐ 9. 20040052819. 03 Oct 03. 18 Mar 04. Sol-fusin: use of gp64-6his to catalyze membrane fusion. Kingsley, David H., et al. 424/204.1; 424/450 435/320.1 435/325 435/458 435/69.1 514/44 530/350 536/23.2 C07H021/04 A61K048/00 A61K039/12 C07K014/005 A61K009/127 C12N015/88.

☐ 10. 20030212026. 09 Dec 02. 13 Nov 03. Immunostimulatory nucleic acids. Krieg, Arthur M., et al. 514/44; A61K048/00.

☐ 11. 20030181406. 06 May 02. 25 Sep 03. CpG-like nucleic acids and methods of use thereof. Schetter, Christian, et al. 514/44; A61K048/00.

☐ 12. 20030180320. 18 Oct 99. 25 Sep 03. ATTENUATED SALMONELLA STRAIN USED AS A VEHICLE FOR ORAL IMMUNIZATION. DARJI, AYUB, et al. 424/200.1; 424/258.1 435/252.3 A61K039/112 C12N001/21.

☐ 13. 20030166589. 05 Jun 01. 04 Sep 03. Method and pharmaceutical composition for the treatment of multiple sclerosis. Karin, Nathan. 514/44; 424/185.1 A61K048/00 A61K039/00.

h e b b g e e e f e e e e b hh che

☐ 14. 20030157059. 08 Jan 02. 21 Aug 03. Feline interleukin-12 as immunostimulant. Lutz, Hans, et al. 424/85.2; 514/44 A61K048/00 A61K038/20.

☐ 15. 20030096778. 13 Jun 02. 22 May 03. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef. Shiver, John W, et al. 514/44; 424/184.1 A61K048/00 A61K039/00.

☐ 16. 20020086841. 25 Jun 01. 04 Jul 02. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis. Karin, Nathan, et al. 514/44; 536/23.5 A61K048/00 C07H021/04.

☐ 17. 20020015693. 08 Aug 01. 07 Feb 02. IL-12 enhancement of immune responses to T-independent antigens. Metzger, Dennis W., et al. 424/85.2; 424/244.1 424/93.6 514/44 514/54 A61K039/09 A61K048/00 A61K031/715.

☐ 18. 6821957. 26 Sep 01; 23 Nov 04. Vectors and methods for immunization or therapeutic protocols. Krieg; Arthur M., et al. 514/44; 424/93.2 435/320.1 435/455 435/91.4. A61K048/00.

☐ 19. 6576757. 28 Nov 00; 10 Jun 03. Polynucleotides encoding flavivirus and alphavirus multivalent antigenic polypeptides. Punnonen; Juha, et al. 536/23.72; 424/184.1 424/204.1 424/218.1 424/228.1 536/23.1. C07H021/04 A61K039/12 A01N043/04.

☐ 20. 6569435. 28 Nov 00; 27 May 03. Flavivirus and alphavirus recombinant antigen libraries. Punnonen; Juha, et al. 424/202.1; 424/204.1 424/234.1 424/236.1 424/274.1 435/320.1 435/6 514/44. A61K039/12 A61K039/295 A01N043/04.

Generate Collection | Print

Terms	Documents
L5 and L8	26

Prev Page Next Page Go to Doc#

h e b b g e e e f e e e e b hh che

Generate Collection | Print

Search Results - Record(s) 21 through 26 of 26 returned.

☐ 21. 6541011. 10 Feb 99; 01 Apr 03. Antigen library immunization. Punnonen; Juha, et al. 424/204.1; 424/218.1 530/300 530/350. A61K039/12 C07K001/00.

☐ 22. 6339068. 20 May 98; 15 Jan 02. Vectors and methods for immunization or therapeutic protocols. Krieg; Arthur M., et al. 514/44; 424/93.2 435/320.1 435/455 435/91.4 435/91.41 435/91.42. A61K048/00 C12N015/00 C12N015/88.

☐ 23. 6316420. 28 Jul 98; 13 Nov 01. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis. Karin; Nathan, et al. 514/44; 424/93.21 435/320.1 435/325. A61K048/00 A61K035/00 C12N015/63 C12N015/85.

☑ 24. 6303114. 05 Mar 98; 16 Oct 01. IL-12 enhancement of immune responses to T-independent antigens. Metzger; Dennis W., et al. 424/85.2; 424/184.1 424/190.1 424/198.1 514/12 514/2 514/54 514/8 514/885. A61K038/20.

☐ 25. 6271206. 11 Sep 97; 07 Aug 01. Sonic nebulized nucleic acid/cationic liposome complexes and methods for pulmonary gene delivery. Pillai; Raviraj S., et al. 514/44; 424/450 435/320.1 435/455 435/458. A61K048/00 C12N015/88 C12N015/63.

☐ 26. 5985264. 05 Mar 98; 16 Nov 99. IL-12 Stimulation of Neonatal immunity. Metzger; Dennis W., et al. 424/85.2; 424/184.1 424/191.1 424/204.1 424/234.1 424/264.1 424/269.1 424/85.4 530/350. A61K045/05 A61K039/00.

Generate Collection | Print

Terms	Documents
L5 and L8	26

h e b b cg b cc e

09/904,896

=> d his

(FILE 'HOME' ENTERED AT 15:12:26 ON 02 FEB 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:12:44 ON 02 FEB 2005

```
L1       314337 S IMMUNE(W)RESPONSE
L2        19768 S (CARBOHYDRATE OR POLYSACCHARIDE)(3A)ANTIGEN
L3        41126 S (BACTERIA? OR T-CELL(W)INDEPENDENT)(4A)ANTIGEN
L4      1207645 S (LIPID OR GLYCOLIPID OR CARRIER(W)CONJUGATE OR LIPOPOLISACCHA
L5      1263346 S L2 OR L3 OR L4
L6         2197 S L1(8A)L5
L7         1600 S L1(5A)L5
L8          876 S (DNA OR CDNA OR NUCLEIC(W)ACID OR POLYNUCLEOTIDE)(6A)IL-12
L9            0 S L6(S)L8
L10           0 S L6 AND L8
L11          48 S L1(7A)L8
L12           1 S L5 AND L11
L13          28 DUP REM L11 (20 DUPLICATES REMOVED)
L14        1118 S L1(3A)L5
L15          31 S L1(W)L5
L16          28 DUP REM L15 (3 DUPLICATES REMOVED)
L17         803 S L1(2A)L5
L18         454 DUP REM L17 (349 DUPLICATES REMOVED)
L19     3757523 S DIFFICULTY OR PROBLEM OR UNPREDICTAB? OR VARIABLE OR VARY?
L20          41 S L14 AND L19
L21          27 DUP REM L20 (14 DUPLICATES REMOVED)
```

=> d au ti so pi ab 10-27 l21

L21 ANSWER 10 OF 27 MEDLINE on STN

AU Harris J P; Heydt J; Keithley E M; Chen M C

TI Immunopathology of the inner ear: an update.

SO Annals of the New York Academy of Sciences, (1997 Dec 29) 830 166-78.
Ref: 82
Journal code: 7506858. ISSN: 0077-8923.

AB We have reviewed the events of an inner-ear immune response. The perilymph contains antibody, presumably derived from the systemic circulation and CSF, which would allow for neutralization and help with opsonization and complement fixation. The endolymphatic sac contains immunocompetent cells capable of processing and presenting viral or **bacterial antigen**, potentiating the **immune response**, attacking the invaders directly or attacking infected cells, and developing immunoglobulin responses in situ. The early release of mediators such as IL-2 likely emanate from the endolymphatic sac and result in potentiation and regulation of the response and may assist in changes in the SMV, including expression of ICAM-1, which aid in the egress of immune cells from the systemic circulation. PMNs arrive first, followed by T cells and B cells, with secretion of specific antibody a relatively late event. Concomitant with the increase in cellular constituents is the formation of a dense extracellular matrix. The inner ear appears to have remarkable **difficulty** in clearing this matrix, ultimately resulting in ossification. The immune response is unfortunately deleterious to the inner ear, resulting in degeneration of the organ of Corti, stria vascularis, and spiral ganglion. Hearing loss is consistently seen following sterile and virally induced labyrinthitis. The inner ear also appears to be a target for autoimmune disease. While inner-ear damage has been described as part of non-organ-specific autoimmune disease, specific disease against the hearing apparatus is also likely. Experimental paradigms have allowed alterations of both the afferent and efferent limbs of this response; ultimately, with the hope that we can alter the course of the response and the subsequent damage in patients.

L21 ANSWER 11 OF 27 MEDLINE on STN
AU Bot A; Nangpal A; Pricop L; Bogen B; Kaushik A; Bona C A
TI V lambda-light chain genes reconstitute **immune responses** to defined **carbohydrate antigens** or haptens by utilizing different VH genes.
SO Molecular immunology, (1996 Dec) 33 (17-18) 1359-68. Journal code: 7905289. ISSN: 0161-5890.
AB The contribution of the lambda-light chain to the development of peripheral B cell repertoire and generation of specific antibodies to haptens and polysaccharide antigens was studied in genetically manipulated kappa-deficient and lambda 2-transgenic mice. The results clearly demonstrate a non-stoichiometric VH gene family expression in the absence of k-light chain and suggest a non-stochastic pairing between VH and V lambda genes, expressed in the peripheral B cell repertoire. A shift in VH gene utilization in the case of VI lambda + antibodies was evident in response to beta 2-6 fructosan and TNP hapten. These observations demonstrate the availability of compensatory mechanisms in the absence of VK genes and are consistent with the hypothesis that VH gene family expression is controlled by genetic factors from inside the VH locus. Furthermore, genetic factors from outside the VH locus, namely restricted available light chain diversity, may lead to a shift in VH gene utilization in the peripheral B cell repertoire.

L21 ANSWER 12 OF 27 MEDLINE on STN
AU Garnacho Montero J; Shou J; Ortiz Leyba C; Jimenez Jimenez F J; Daly J M
TI Lipids and immune function.
SO Nutricion hospitalaria : organo oficial de la Sociedad Espanola de Nutricion Parenteral y Enteral, (1996 Jul-Aug) 11 (4) 230-7. Ref: 87 Journal code: 9100365. ISSN: 0212-1611.
AB Intravenous lipid emulsions as part of Total Parenteral Nutrition, are now standard in most centers. The most frequently used lipid formula contains predominantly long-chain triglycerides (LCT) of n-6 series . Controversy and concern exist about the immunosuppressive effects of this fuel source mainly based on experimental data because clinical studies are sparse. Some investigators have pointed out that this lipid emulsion impair monocyte, lymphocyte and neutrophil functions although these changes seem to be related to quantity and rate of lipid administration. A new lipid emulsion that contains 50% as medium chain triglycerides is available. The impact of this formula on immune function is unknown although some papers suggest that it produces less deleterious effects on **immune response** than the traditional **lipid** source. Prostaglandins and leukotrienes have numerous effects on immune functions and mediate many of the hemodynamic aspects of the metabolic response to injury. The use of n-3 fatty acids that produce less immunosuppressive eicosanoids have been studied in experimental model with hopeful results. Despite these conflicting data, almost all authors agree that there are no justification for withholding intravenous lipid therapy because they are safe and effective providing essential fatty acids with a high caloric content. Future studies are needed to define the precise composition of lipid emulsions that may **vary** in the different pathologic situations.

L21 ANSWER 13 OF 27 MEDLINE on STN DUPLICATE 2
AU Rothman D; DeLuca P; Zurier R B
TI Botanical **lipids**: effects on inflammation, **immune responses**, and rheumatoid arthritis.
SO Seminars in arthritis and rheumatism, (1995 Oct) 25 (2) 87-96. Ref: 75 Journal code: 1306053. ISSN: 0049-0172.
AB OBJECTIVE: This review discusses the rationale and experimental data that led to clinical trials of certain botanical lipids, mainly gammalinolenic acid (GLA), for the treatment of rheumatoid arthritis (RA). DATA SOURCES: Pertinent articles and reviews, and a bibliographic database in English using the following indexing terms: rheumatoid arthritis, fatty acids, gammalinolenic acid, lymphocytes, and monocytes, were used. STUDY

SELECTION: All clinical trials in which GLA was used to treat arthritis are included in this review. Data from appropriately peer reviewed in vitro and animal experiments evaluating the effects of botanical lipids as regulators of cell activation and immune responses are also reviewed. DATA SYNTHESIS: GLA treatment is associated with clinical improvement in patients with RA, as evaluated by duration of morning stiffness, joint pain and swelling, and ability to reduce other medications. However, studies **vary** in terms of duration, GLA dose, whether or not they were placebo controlled, and, if so, what placebo was used, criteria for evaluation, and use of concomitant medication. Studies done in vitro generally indicated that GLA reduces lymphocyte activation and production of mediators of inflammation. CONCLUSIONS: A small number of studies suggest that GLA is effective treatment for RA patients. Further controlled studies of its use in RA seem warranted.

L21 ANSWER 14 OF 27 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN

AU SANDERS L A M (Reprint); RIJKERS G T; KUIS W; TENBERGENMEEKES A J; DEGRAEFFMEEDER B R; HIEMSTRA I; ZEGERS B J M

TI DEFECTIVE ANTIPNEUMOCOCCAL POLYSACCHARIDE ANTIBODY-RESPONSE IN CHILDREN WITH RECURRENT RESPIRATORY-TRACT INFECTIONS

SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (JAN 1993) Vol. 91, No. 1, Part 1, pp. 110-119.
ISSN: 0091-6749.

AB Background: Recurrent pyogenic infections are known to occur in patients with an impaired resPonse to PolYsaccharide antigens. We investigated the occurrence of deficient responses to pneumococcal capsular polysaccharides in patients with recurrent respiratory tract and recurrent systemic infections.

Methods: Forty-five patients, 1.7 to 17.1 years of age, were immunized with 23-valent pneumococcal polysaccharide vaccine. Antibody levels to seven pneumococcal serotypes (3, 4, 6A, 9N, 14, 19F, 23F) were determined by ELISA before and after immunization. In addition, patients received a booster immunization with diphtheria toxoid, tetanus toxoid, and poliomyelitis virus vaccine.

Results: Thirty-five patients had normal serum immunoglobulin levels. Five of these patients (14%) had low antipneumococcal preimmunization antibody levels and failed to respond to pneumococcal vaccination, whereas the response to booster immunization with protein antigens was appropriate. Three patients were younger than 3 years old, and one had a family history of IgG2 deficiency. Low IgG developed in a fifth patient during follow-up. Ten patients had a humoral immunodeficiency. Seven of these patients failed to respond to pneumococcal vaccination.

Conclusions: We conclude that a defective **immune response** to **polysaccharide antigens** in patients requires long-term follow-up to distinguish transient maturational delay from a persistent selective impaired response to polysaccharide antigens, which on occasion may precede the development of humoral immunodeficiency disease.

L21 ANSWER 15 OF 27 MEDLINE on STN DUPLICATE 3

AU Aaberge I S; North R J; Groeng E C; Lovik M

TI Antibody response to pneumococcal polysaccharide vaccine in young, adult and old mice.

SO Scandinavian journal of immunology, (1993 Jul) 38 (1) 17-30.
Journal code: 0323767. ISSN: 0300-9475.

AB The anti-pneumococcal antibody response was studied in young (5-week-old) and adult (10-week-old) BALB/c and CBA/J mice and in adult (9-10-week-old) and old (12-, 18- and 24-month-old) AB6F1 and B6D2F1 mice after s.c. immunization with a 23-valent pneumococcal polysaccharide vaccine. Both young and adult mice showed a significant IgM antibody response to the vaccine 6 days after immunization with 1-11 micrograms antigen. There were significant immune responses to serotypes 1, 2, 4 and 7F in contrast to small responses to serotypes 14, 19F and 23F after immunization with

the vaccine. One month after immunization, there were only marginal differences in IgM anti-pneumococcal antibody levels to the vaccine (anti-PPS) between immunized and unimmunized BALB/c mice, whereas in CBA/J mice the anti-PPS remained higher in immunized than in unimmunized mice. Immunization of old mice induced a significant IgM antibody response 6 days after immunization, but the anti-PPS thereafter decreased rapidly towards preimmunization values in AB6F1 mice. A significant IgG anti-PPS was not detected in any of the mice studied. The IgA anti-PPS tended to **vary** over time with no consistent pattern. It is important to carefully consider age and strain of the mice used when studying the **immune response** to pneumococcal **polysaccharide antigens**.

L21 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
AU Wysocki, L. J.; Creadon, G.; Lehmann, K. R.; Cambier, J. C.
TI B-cell proliferation initiated by Ia cross-linking and sustained by interleukins leads to class switching but not somatic mutation in vitro
SO Immunology (1992), 75(1), 116-21
CODEN: IMMUAM; ISSN: 0019-2805
AB Somatic mutations that are acquired by antibody V genes of antigen-stimulated B cells ultimately provide the clonal diversity from which memory B cells are selected during immune responses to T-cell-dependent antigens. Somatic mutations apparently are not acquired when B cells are stimulated by mitogens nor when they participate in **immune responses** to **T-cell-independent antigens**. Since the basis of T-cell-dependent humoral immunity is T-cell recognition of processed antigen in the context of class II major histocompatibility glycoproteins (Ia) on the B-cell surface, the authors sought to determine whether the ligation of Ia on B cells induces somatic mutation. B cells were stimulated in vitro by a procedure in which their proliferation was dependent upon ligation of surface Ia with antibody. Sequences of hybridoma V genes derived from these B cells revealed no somatic mutations despite prolonged stimulation in vitro and the induction of Ig secretion and switching to isotypes characteristic of T cell-dependent humoral immunity. It is infered that Ia-mediated signalling and isotype switching are not causally related to somatic mutation. The avenue of the differentiation that leads to somatic mutation in memory B cells is apparently separable from that leading to proliferation, Ig secretion and switching.

L21 ANSWER 17 OF 27 MEDLINE on STN DUPLICATE 5
AU Tolo K
TI Periodontal disease mechanisms in immunocompromised patients.
SO Journal of clinical periodontology, (1991 Jul) 18 (6) 431-5. Ref: 48
Journal code: 0425123. ISSN: 0303-6979.
AB Deficiency in the number and function of phagocytes is associated with gingival inflammation and periodontitis. A hereditary deficiency in membrane glycoproteins involved in granulocyte adherence causes impaired chemotaxis, reduced phagocytosis and periodontal **problems**. Virus infections of antigen-presenting cells interfere with immune responses and lead to seriously increased susceptibility to infections with bacteria which cause no **problems** in normal patients. Increased levels of IgG antibodies may limit penetration of antigens in the tissues, but at the cost of local inflammation and tissue injury. Mucosal inflammatory disease with increased local formation of IgG is more frequent in IgA deficient patients. The immunological homeostasis depends on a balance between the respective classes and subclasses of antibodies. Deficiencies in the IgA system may contribute to a disturbed balance of the humoral **immune response** to critical **antigens** from oral **bacteria**. A disproportional increase in IgG1 and IgG3 antibodies may persistently activate complement, stimulate the inflammatory activity and cause tissue injury.

L21 ANSWER 18 OF 27 MEDLINE on STN DUPLICATE 6
AU Lloyd K O
TI Humoral **immune responses** to tumor-associated **carbohydrate antigens**.
SO Seminars in cancer biology, (1991 Dec) 2 (6) 421-31. Ref: 91
Journal code: 9010218. ISSN: 1044-579X.
AB Antibodies to carbohydrate structures are quite commonly found in human sera. Normal individuals, as well as individuals with autoimmune diseases and cancer, produce antibodies reacting with a variety of carbohydrate determinants. These determinants can be expressed on glycoproteins, mucins or glycosphingolipids. For understanding a possible immune response to cancer, the challenge is to determine which, if any, of the serum antibodies are related to the tumor state. This **problem** has been approached by analyzing the specificity of serum antibodies and, more recently, by producing monoclonal antibodies from the lymphocytes of cancer patients. Malignant melanoma and lung cancer have been the main focus of the monoclonal antibody approach. Melanoma patients' lymphocytes have, in general, yielded anti-ganglioside antibodies whereas anti-neutral glycolipid antibodies were isolated from lung cancer patients. Although these studies provide reagents for potential use in the in vivo diagnosis and therapy of cancer, the significance of these antibodies for an immune response to cancer needs to be further explored.

L21 ANSWER 19 OF 27 MEDLINE on STN DUPLICATE 7
AU Kannagi R; Zenita K; Hirashima K; Takada A
TI Analysis of VH genes which encode the **variable** region of monoclonal antibodies directed to cancer-associated carbohydrate antigens.
SO Gan to kagaku ryoho. Cancer & chemotherapy, (1989 Mar) 16 (3 Pt 2) 662-79. Ref: 30
Journal code: 7810034. ISSN: 0385-0684.
AB **Immune responses** against cancer-associated, **carbohydrate antigens** are investigated by studying idiotypic determinants of specific antibodies with monoclonal anti-idiotypic antibodies, and by analyzing the structure of VH genes which encode the V region of the anti-carbohydrate antibodies. Four syngenic anti-idiotypic antibodies towards monoclonal antibodies which are specific to the sialyl Lewis A antigen and two kinds of SSEA-1 related antigens (sialyl SSEA-1 and fucosul SSEA-1) were obtained. Antibodies directed to carbohydrate antigens were mostly of IgM isotype, indicating these antigens are T-independent antigens, while anti-idiotypic monoclonal antibodies directed to those antibodies were mostly of IgG isotype, suggesting that T cells participate actively in the anti-idiotypic response. The Northern blotting analysis of VH genes of monoclonal antibodies directed to negatively-charged carbohydrate antigens such as gangliosides or sulfated glycolipids expressed the VH gene family J558 (group 1), followed by J606 (group 6) and Q52 (group 2) families. On the other hand, monoclonal antibodies directed to SSEA-1 related neutral carbohydrate antigens expressed VH genes of a minor family such as X24 (group 4), V31 (group 9), or 7183 (group 5). The same VH family as expressed in anti-SSEA-1 antibody (x24) was also expressed in the antibodies such as anti-i and anti-I antibodies, which are directed to the synthetic precursors of the SSEA-1 antigen. In either case, the antibodies directed to one particular carbohydrate antigen tended to express the VH gene of one particular family exclusively. This suggests idiotypic homogeneity of the anti-carbohydrate antibodies.

L21 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2005 ACS on STN
AU Kannagi, Reiji; Miyake, Masayuki; Zenita, Kouichi; Mori, Yumiko
TI Carbohydrate antigens in cancer cells
SO Kagaku to Seibutsu (1988), 26(4), 220-34
CODEN: KASEAA; ISSN: 0453-073X
AB A review with 45 refs. on disorders of carbohydrate chain structure in cancer cells, the roles of carbohydrate chains in normal and malignant cells, the structure and role of stage-specific embryonic antigen-1

(SSEA-1), **immune responses** to **carbohydrate antigens**, and the possibility and **problems** in cancer therapy using monoclonal antibodies specific for cancer-associated carbohydrate antigens.

L21 ANSWER 21 OF 27 MEDLINE on STN DUPLICATE 8
AU Douglas-Jones A G; Wade S; Kent D; Vaughan R; Watson J D
TI Immunity to leprosy. III. The in vitro induction of B lymphocyte proliferation by mycobacteria.
SO International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, (1986 Mar) 54 (1) 63-70.
Journal code: 8505819. ISSN: 0148-916X.
AB The development of murine proliferative response assays has been initiated to begin to evaluate T-lymphocyte responses to the antigens of Mycobacterium leprae. In this study, M. leprae and 13 related strains of mycobacteria have been tested for stimulatory effects in proliferation assays using murine spleen, thymus or lymph node cultures. A number of mycobacteria were found to directly stimulate the proliferation of spleen and lymph node cells of all mouse strains tested including C3H/HeJ mice. Thymocyte cultures showed no response. The mitogenic effects of mycobacteria in spleen cultures were not dependent upon the presence of T cells or adherent cells, and resulted in the production of antibody-forming cells. Thus, these bacteria acted as polyclonal B-cell mitogens and could be readily distinguished from the lipopolysaccharide of Gram-negative bacteria by their mitogenic activity on C3H/HeJ spleen cells. The species of mycobacteria which exhibit direct mitogenic effects in spleen and lymph node cultures are a particular **problem** when specific **immune responses** to the **antigens** of these **bacteria** are compared. Such comparisons are necessary if in vitro assays are to be used to determine the nature of crossreactive antigens between M. leprae and other mycobacteria.

L21 ANSWER 22 OF 27 MEDLINE on STN
AU Miller T E; Burnham S
TI Antigen presentation as a factor in the protective immune response to renal infection.
SO Clinical and experimental immunology, (1975 Nov) 22 (2) 265-78.
Journal code: 0057202. ISSN: 0009-9104.
AB Host protection against renal infection may be augmented by active immunization against the causative organism. In these experiments we have investigated the effect of **varying** amounts and methods of presentation of **bacterial antigen** on the seconday **immune response**. Primary immunization with **varying** amounts of both killed and live antigen did not affect the nature of the secondary immune response although active renal infection did have a noticeable effect on the titre of serum antibody during the primary immune response. The experiments confirmed the presence of immunological memory to the somatic antigen of E. coli and showed that memory persisted for at least 6 months after primary immunization. Experiments have also been carried out which have demonstrated that memory to the somatic antigen of E. coli is carried by the B lymphocyte.

L21 ANSWER 23 OF 27 MEDLINE on STN DUPLICATE 9
AU Ghaffar A; James K
TI The effect of antilymphocytic antibody on the humoral immune response of different strains of mice. IV. **Variable** effect of individual ALG preparations on the **immune response** to type 3 **polysaccharide antigen**.
SO Immunology, (1974 Jan) 26 (1) 11-22.
Journal code: 0374672. ISSN: 0019-2805.

L21 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2005 ACS on STN
AU Koelsch, E.; Diller, Eva; Weber, G.; Davies, A. J. S.

TI Genetics of the immune response. I. **Immune response** to the **phage** fd in high and low responding inbred strains of mice

SO European Journal of Immunology (1971), 1(3), 201-10
CODEN: EJIMAF; ISSN: 0014-2980

AB The inactivation curve of bacteriophage fd in inbred strains of mice by specific antisera followed initially first order kinetics, finally leveling off gradually. The strength of the antisera was characterized primarily by the velocity constant K of the inactivation kinetics. Two other methods, endpoint and plateau determination, were used for the anal. of selected **problems**. The threshold dose for priming for a secondary response varied widely. Low-responding strains had a 100- to 1000-fold higher threshold dose than high-responding strains. High responsiveness was dominant over low responsiveness in genetic anal. and inherited as a single dominant trait. The cooperating role of thymus-derived cells and of macrophages was tested. The previous uptake of antigen by macrophages probably prevented induction of high zone paralysis. No evidence was found for macrophages being responsible for high and low responsiveness. The **immune response** to **phage** fd was strongly thymus dependent.

L21 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2005 ACS on STN

AU Ortiz-Ortiz, Librado; Rivas-Gomez, Carlos; Bojalil, Luis F.

TI Tuberculin activity of somatic fractions obtained from Mycobacterium

SO Revista Latinoamericana de Microbiologia (1971), 13(1), 35-9
CODEN: RLMIAA; ISSN: 0034-9771

AB M. bovis strain BCG suspension in 0.15M NaCl was subjected to cell rupture, centrifuged, and supernatant 80% saturated with (NH4)2SO4, and dialyzed or passed through a Sephadex G-25 column. The resulting salt-free product was adjusted to pH 3 with 0.1M HOAc; the precipitate was washed with HOAc to remove carbohydrate, dissolved in water at pH 8, dialyzed against 0.05M phosphate buffer (pH 6.5), and passed through a DEAE-cellulose column. The material was gradient-eluted with 0.05M phosphate buffer and 0.05-1.0M KCl, the eluate being continuously monitored for protein at 280 nm. Four carbohydrate-free protein fractions (I-IV) were obtained containing **variable** amts. of nucleic acids. Guinea pigs were sensitized with 1 mg M. boris strain BCG in Freund's incomplete adjuvant; skin tests were made by injecting fractions I-IV, and induration diams. were measured after 1, 4, and 24 hr, diams. <5 mm being considered neg. With 0.25-1.0 μg protein, all fractions produced a delayed-type hypersensitivity reaction. Nonsensitized animals showed no inflammatory reaction. At 5 μg protein, fractions II and IV evoked an immediate reaction in sensitized animals and caused an inflammatory reaction in nonsensitized animals. It is suggested that nucleoproteins in fractions II-IV are responsible for the immediate-type reactions and that the nonspecific reaction in normal animals is due to ribosome material in III and IV.

L21 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2005 ACS on STN

AU Smith, James William; Barnett, Jack A.; Sanford, Jay P.

TI Heterogeneity of immune response to the somatic (O) antigens of Proteus mirabilis

SO Journal of Immunology (1970), 105(2), 404-10
CODEN: JOIMA3; ISSN: 0022-1767

AB A variation in the antibody response to antigenically differing somatic antigens (O) of P. mirabilis was noted in rats. Certain strains induced the synthesis of 2-mercaptoethanol sensitive (2-MES), or IgM, antibody, whereas other strains led to the rapid appearance of 2-mercaptoethanol resistant (2-MER), or IgG, antibody. The **varying** response was not due to the differences in the quantity of lipopolysaccharide administered and was demonstrated when animals were challenged either sep. or simultaneously with 2 strains. These differences in antibody response were not solely dependent upon antigenic mass administered as demonstrated

by the failure of a 100-fold increase in antigenic mass to convert a 2-MES response to that of 2-MER, although a 100-fold diminution in antigenic mass converted the 2-MER response to 2-MES. No difference in the carbohydrate composition of the lipopolysaccharides obtained from these strains was apparent from gas chromatographic anal. Thus, these studies demonstrate that the immune response of a given host can be determined not only by the quantity of antigen but also by differing characteristics of lipopolysaccharides from a single bacterial species.

L21 ANSWER 27 OF 27 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

AU Bot, Adrian; Nangpal, Alpana; Pricop, Luminita; Bogen, Bjarne; Kaushik, Azad; Bona, Constantin A. [Reprint author]

TI V-light chain genes reconstitute **immune responses** to defined **carbohydrate antigens** or haptens by utilizing different V-H genes.

SO Molecular Immunology, (1996 (1997)) Vol. 33, No. 17-18, pp. 1359-1368. . CODEN: MOIMD5. ISSN: 0161-5890.

AB The contribution of the lambda-light chain to the development of peripheral B cell repertoire and generation of specific antibodies to haptens and polysaccharide antigens was studied in genetically manipulated kappa-deficient and lambda-2-transgenic mice. The results clearly demonstrate a non-stoichiometric V-H gene family expression in the absence of k-light chain and suggest a non-stochastic pairing between V-H and V-lambda genes, expressed in the peripheral B cell repertoire. A shift in V-H gene utilization in the case of Vl-lambda+ antibodies was evident in response to beta-2-6 fructosan and TNP hapten. These observations demonstrate the availability of compensatory mechanisms in the absence of V-K genes and are consistent with the hypothesis that V-H gene family expression is controlled by genetic factors from inside the V-H locus. Furthermore, genetic factors from outside the V-H locus, namely restricted available light chain diversity, may lead to a shift in V-H gene utilization in the peripheral B cell repertoire.

09/924,896

```
=> d his

     (FILE 'HOME' ENTERED AT 15:12:26 ON 02 FEB 2005)

     FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:12:44 ON 02 FEB
     2005
L1        314337 S IMMUNE(W)RESPONSE
L2         19768 S (CARBOHYDRATE OR POLYSACCHARIDE)(3A)ANTIGEN
L3         41126 S (BACTERIA? OR T-CELL(W)INDEPENDENT)(4A)ANTIGEN
L4       1207645 S (LIPID OR GLYCOLIPID OR CARRIER(W)CONJUGATE OR LIPOPOLISACCHA
L5       1263346 S L2 OR L3 OR L4
L6          2197 S L1(8A)L5
L7          1600 S L1(5A)L5
L8           876 S (DNA OR CDNA OR NUCLEIC(W)ACID OR POLYNUCLEOTIDE)(6A)IL-12
L9             0 S L6(S)L8
L10            0 S L6 AND L8
L11           48 S L1(7A)L8
L12            1 S L5 AND L11
L13           28 DUP REM L11 (20 DUPLICATES REMOVED)
L14         1118 S L1(3A)L5
L15           31 S L1(W)L5
L16           28 DUP REM L15 (3 DUPLICATES REMOVED)

=> d bib ab l12

L12  ANSWER 1 OF 1  SCISEARCH  COPYRIGHT (c) 2005 The Thomson Corporation.  on
     STN
AN   1999:988238  SCISEARCH
GA   The Genuine Article (R) Number: 265ZD
TI   Intravenous cytokine gene delivery by lipid-DNA complexes
     controls the growth of established lung metastases
AU   Dow S W (Reprint); Elmslie R E; Fradkin L G; Liggitt D H; Heath T D;
     Willson A P; Potter T A
CS   NATL JEWISH MED & RES CTR, DEPT MED, DIV BASIC IMMUNOL, 1400 JACKSON ST,
     5TH FLOOR, GOODMAN BLDG, DENVER, CO 80206 (Reprint); UNIV COLORADO, DIV
     MED ONCOL, DENVER, CO 80262; VET CANC SPECIALISTS, ENGLEWOOD, CO 80110;
     VALENTS INC, BURLINGAME, CA 94010; UNIV WISCONSIN, SCH PHARM, MADISON, WI
     53706; UNIV COLORADO, CTR CANC, DEPT IMMUNOL, DENVER, CO 80262
CYA  USA
SO   HUMAN GENE THERAPY, (10 DEC 1999) Vol. 10, No. 18, pp. 2961-2972.
     Publisher: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY
     10538.
     ISSN: 1043-0342.
DT   Article; Journal
FS   LIFE
LA   English
REC  Reference Count: 37
     *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
AB      Local expression of cytokine genes by ex vivo transfection or
     intratumoral gene delivery can control the growth of cutaneous tumors.
     However, control of tumor metastases by conventional nonviral gene therapy
     approaches is more difficult. Intravenous injection of lipid-DNA
     complexes containing noncoding plasmid DNA can significantly inhibit the
     growth of early metastatic lung tumors. Therefore, we hypothesized that
     delivery of a cytokine gene by lipid-plasmid DNA complexes could
     induce even greater antitumor activity in mice with established lung
     metastases. The effectiveness of treatment with lipid-DNA
     complexes containing the IL-2 or IL-12 gene was compared with the
     effectiveness, of treatment with complexes containing noncoding (empty
     vector) DNA. Treatment effects were evaluated in mice with either early
     (day 3) or late (day 6) established lung tumors. Lung tumor burdens and
     local intrapulmonary immune responses were assessed.
     Treatment with either noncoding plasmid DNA or with the IL-2 or
     IL-12 gene significantly inhibited the growth of early
```

tumors. However, only treatment with the IL-2 or IL-12 gene induced a significant reduction in lung tumor burden in mice with more advanced metastases. Furthermore, the reduction in tumor burden was substantially greater than that achieved by treatment with recombinant cytokines, Treatment with the IL-2 or IL-12 gene was accompanied by increased numbers of NK cells and CD8(+) T cells within lung tissues, increased cytotoxic activity, and increased local production of IFN-gamma by lung tissues, compared with treatment with noncoding DNA. Thus, cytokine gene delivery to the lungs by means of intravenously administered **lipid**-DNA complexes may be an effective method of controlling lung tumor metastases.

=> d au ti so pi 1-28 l13

L13 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Sun, Yong-tao; Wang, Fu-xiang; Sun, Yong-nian; Xu, Zhe; Wang, Lin-xu; Liu, Juan; Bai, Xue-fan; Huang, Chang-xing
TI Modulation of cellular and humoral immune responses to anHIV-1 DNA vaccine by interleukin-12 and interleukin-18 DNA immunization
SO Journal of Medical Colleges of PLA (2004), 19(4), 205-210
CODEN: JMCPE6; ISSN: 1000-1948

L13 ANSWER 2 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Okada, Masaji [Reprint Author]; Tanaka, Takao; Kita, Yoko; Kuwayama, Sachiko; Muraki, Yumiko; Kanamaru, Noriko; Hashimoto, Satomi; Takai, Hiroko; Okada, Chika; Sakaguchi, Yayoi; Furukawa, Izumi; Yamada, Kyoko; Saito, Izumu; Matsumoto, Makoto; Sakatani, Mitsunori
TI Novel Therapeutic DNA Vaccination using adenovirus vector/ IL-6 DNA+ IL-6R DNA+ gp130 against Tuberculosis by the Augmentation of in vivo Cytotoxic Activity.
SO FASEB Journal, (2004) Vol. 18, No. 4-5, pp. Abst. 558.17.
http://www.fasebj.org/. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. Washington, District of Columbia, USA. April 17-21, 2004. FASEB.
ISSN: 0892-6638 (ISSN print).

L13 ANSWER 3 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Baek K M; Ko S Y; Lee M; Lee J S; Kim J O; Ko H J; Lee J W; Lee S H; Cho S N; Kang C Y (Reprint)
TI Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65
SO VACCINE, (8 SEP 2003) Vol. 21, No. 25-26, pp. 3684-3689.
Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND.
ISSN: 0264-410X.

L13 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Siddiqui, Afzal A.; Phillips, Troy; Charest, Hugues; Podesta, Ron B.; Quinlin, Martha L.; Pinkston, Justin R.; Lloyd, Jenny D.; Pompa, Janet; Villalovos, Rachael M.; Paz, Michelle
TI Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation
SO Vaccine (2003), 21(21-22), 2882-2889
CODEN: VACCDE; ISSN: 0264-410X

L13 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Zhao, Ping; Gao, Jun; Wang, Hongwei; Cao, Jie; Qi, Zhongtian
TI Enhancement of cellular **immune responses** to hepatitis B virus fusion antigen **DNA** vaccine in mice by murine **IL -12**
SO Bingdu Xuebao (2003), 19(1), 83-85

CODEN: BIXUEA; ISSN: 1000-8721

L13 ANSWER 6 OF 28 MEDLINE on STN DUPLICATE 1
AU Tapia Esther; Perez-Jimenez Eva; Lopez-Fuertes Laura; Gonzalo Rosa; Gherardi M Magdalena; Esteban Mariano
TI The combination of **DNA** vectors expressing **IL-12** + IL-18 elicits high protective **immune response** against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
SO Microbes and infection / Institut Pasteur, (2003 Feb) 5 (2) 73-84.
Journal code: 100883508. ISSN: 1286-4579.

L13 ANSWER 7 OF 28 MEDLINE on STN DUPLICATE 2
AU Shan Mei-Mei; Liu Ke-Zhou; Fang Hai-Lin; Chen Zhi
TI **DNA immune responses** induced by codelivery of **IL-12** expression vectors with hepatitis C structural antigens.
SO Hepatobiliary & pancreatic diseases international : HBPD INT, (2002 Nov) 1 (4) 553-7.
Journal code: 101151457. ISSN: 1499-3872.

L13 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Zimmermann, Stefan; Heeg, Klaus
TI CpG motifs in vaccination
SO Vaccine Delivery Strategies (2002), 139-161. Editor(s): Dietrich, Guido; Goebel, Werner. Publisher: Horizon Scientific Press, Wymondham, UK.
CODEN: 69ELHT; ISBN: 1-898486-48-4

L13 ANSWER 9 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Chen H W; Pan C H; Huan H W; Liau M Y; Chiang J R; Tao M H (Reprint)
TI Suppression of immune response and protective immunity to a Japanese encephalitis virus DNA vaccine by coadministration of an IL-12-expressing plasmid
SO JOURNAL OF IMMUNOLOGY, (15 JUN 2001) Vol. 166, No. 12, pp. 7419-7426.
Publisher: AMER ASSOC IMMUNOLOGISTS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.
ISSN: 0022-1767.

L13 ANSWER 10 OF 28 MEDLINE on STN DUPLICATE 3
AU Pertmer T M; Oran A E; Madorin C A; Robinson H L
TI Th1 genetic adjuvants modulate immune responses in neonates.
SO Vaccine, (2001 Feb 8) 19 (13-14) 1764-71.
Journal code: 8406899. ISSN: 0264-410X.

L13 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Ferrone, Cristina R.; Gold, Jason S.; Perales, Miguel-Angel; Wolchok, Jedd D.; Engelhorn, Manuel E.; Ramirez-Montagut, Teresa; Houghton, Alan N.
TI IL-12 and CD40 ligand DNA as molecular adjuvants for hgp100 immunization
SO Surgical Forum (2001), 52, 231-233
CODEN: SUFOAX; ISSN: 0071-8041

L13 ANSWER 12 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Tudor D; Riffault S; Carrat C; Lefevre F; Bernoin M; Charley B (Reprint)
TI Type IIFN modulates the immune response induced by DNA vaccination to pseudorabies virus glycoprotein C
SO VIROLOGY, (20 JUL 2001) Vol. 286, No. 1, pp. 197-205.
Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0042-6822.

L13 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

AU Du, Dewei; Zhou, Yongxing; Jiao, Chengsong; Feng, Zhihua; Li, Jinge; Lian, Jianqi; Yao, Zhiqiang
TI Interleukin 12 affects immunization of hepatitis B DNA vaccine in mice
SO Disi Junyi Daxue Xuebao (2000), 21(7), 805-807
CODEN: DJDXEG; ISSN: 1000-2790

L13 ANSWER 14 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Kuo M L (Reprint); Chen L C; Huang C C; Huang J L
TI The **immune responses** in asthmatic mice with **DNA** vaccine containing allergen and **IL-12** cDNA sequences
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (JAN 2000) Vol. 105, No. 1, Part 2, Supp. [S], pp. 349-349.
Publisher: MOSBY-YEAR BOOK INC, 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318.
ISSN: 0091-6749.

L13 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Asakura, Y.; Liu, L.-J.; Shono, N.; Hinkula, J.; Kjerrstrom, A.; Aoki, I.; Okuda, K.; Wahren, B.; Fukushima, J.
TI Th1-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production
SO Clinical and Experimental Immunology (2000), 119(1), 130-139
CODEN: CEXIAL; ISSN: 0009-9104

L13 ANSWER 16 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Kuo, M. L. [Reprint author]; Chen, L. C. [Reprint author]; Huang, C. C. [Reprint author]; Huang, J. L. [Reprint author]
TI The **immune responses** in asthmatic mice with **DNA** vaccine containing allergen and **IL-12** cDNA sequences.
SO Journal of Allergy and Clinical Immunology, (Jan., 2000) Vol. 105, No. 1 part 2, pp. S116. print.
Meeting Info.: 56th Annual Meeting of the American Academy of Allergy, Asthma and Immunology. San Diego, California, USA. March 03-08, 2000. American Academy of Allergy, Asthma and Immunology.
CODEN: JACIBY. ISSN: 0091-6749.

L13 ANSWER 17 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Dow S W (Reprint); Elmslie R E; Fradkin L G; Liggitt D H; Heath T D; Willson A P; Potter T A
TI Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases
SO HUMAN GENE THERAPY, (10 DEC 1999) Vol. 10, No. 18, pp. 2961-2972.
Publisher: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY 10538.
ISSN: 1043-0342.

L13 ANSWER 18 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Sin J I; Kim J J; Arnold R L; Shroff K E; McCallus D; Pachuk C; McElhiney S P; Wolf M W; PompadeBruin S J; Higgins T J; Ciccarelli R B; Weiner D B (Reprint)
TI IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4(+) T cell-mediated protective immunity against herpes simplex virus-2 challenge
SO JOURNAL OF IMMUNOLOGY, (1 MAR 1999) Vol. 162, No. 5, pp. 2912-2921.
Publisher: AMER ASSOC IMMUNOLOGISTS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.
ISSN: 0022-1767.

L13 ANSWER 19 OF 28 MEDLINE on STN DUPLICATE 4
AU Pan C H; Chen H W; Tao M H
TI Modulation of immune responses to DNA vaccines by codelivery of cytokine genes.
SO Journal of the Formosan Medical Association = Taiwan yi zhi, (1999 Nov) 98 (11) 722-9. Ref: 68
Journal code: 9214933. ISSN: 0929-6646.

L13 ANSWER 20 OF 28 MEDLINE on STN DUPLICATE 5
AU Gurunathan S; Irvine K R; Wu C Y; Cohen J I; Thomas E; Prussin C; Restifo N P; Seder R A
TI CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.
SO Journal of immunology (Baltimore, Md. : 1950), (1998 Nov 1) 161 (9) 4563-71.
Journal code: 2985117R. ISSN: 0022-1767.

L13 ANSWER 21 OF 28 MEDLINE on STN DUPLICATE 6
AU Kim J J; Maguire H C Jr; Nottingham L K; Morrison L D; Tsai A; Sin J I; Chalian A A; Weiner D B
TI Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype.
SO Journal of interferon & cytokine research : official journal of the International Society for Interferon and Cytokine Research, (1998 Jul) 18 (7) 537-47.
Journal code: 9507088. ISSN: 1079-9907.

L13 ANSWER 22 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Tueting, Thomas [Reprint author]; Gambotto, Andrea; Deleo, Albert B.; Storkus, Walter J.
TI Adjuvant administration of plasmid **DNA** expressing **IL-12** enhances the induction of anti-melanoma **immune responses** with plasmid DNA encoding the murine melanoma protein TRP-2.
SO Journal of Investigative Dermatology, (April, 1998) Vol. 110, No. 4, pp. 486. print.
Meeting Info.: Annual Meeting of the International Investigative Dermatology. Cologne, Germany. May 7-10, 1998. The Society for Investigative Dermatology, Inc.
CODEN: JIDEAE. ISSN: 0022-202X.

L13 ANSWER 23 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Tuting T (Reprint); Gambotto A; DeLeo A B; Storkus W J
TI Adjuvant administration of plasmid **DNA** expressing **IL-12** enhances the induction of anti-melanoma **immune responses** with plasmid DNA encoding the murine melanosomal protein TRP-2
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (APR 1998) Vol. 110, No. 4, pp. 486-486.
Publisher: BLACKWELL SCIENCE INC, 350 MAIN ST, MALDEN, MA 02148.
ISSN: 0022-202X.

L13 ANSWER 24 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Tueting, Thomas [Reprint author]; Gambotto, Andrea; Deleo, Albert B.; Storkus, Walter J.
TI Adjuvant administration of plasmid **DNA** expressing **IL-12** enhances the induction of anti-melanoma **immune responses** with plasmid DNA encoding the murine melanosomal protein TRP-2.
SO Journal of Dermatological Science, (March, 1998) Vol. 16, No. SUPPL. 1,

pp. S14. print.
Meeting Info.: Third Joint Meeting of the European Society for Dermatological Research, Japanese Society for Investigative Dermatology, Society for Investigative Dermatology. Cologne, Germany. May 7-10, 1998. European Society for Dermatological Research; Japanese Society for Investigative Dermatology; Society for Investigative Dermatology.
CODEN: JDSCEI. ISSN: 0923-1811.

L13 ANSWER 25 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Klinman D M (Reprint); Yamshchikov G; Ishigatsubo Y
TI Contribution of CpG motifs to the immunogenicity of DNA vaccines
SO JOURNAL OF IMMUNOLOGY, (15 APR 1997) Vol. 158, No. 8, pp. 3635-3639.
Publisher: AMER ASSOC IMMUNOLOGISTS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.
ISSN: 0022-1767.

L13 ANSWER 26 OF 28 MEDLINE on STN DUPLICATE 7
AU Gurunathan S; Sacks D L; Brown D R; Reiner S L; Charest H; Glaichenhaus N; Seder R A
TI Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
SO Journal of experimental medicine, (1997 Oct 6) 186 (7) 1137-47.
Journal code: 2985109R. ISSN: 0022-1007.

L13 ANSWER 27 OF 28 MEDLINE on STN DUPLICATE 8
AU Kim J J; Ayyavoo V; Bagarazzi M L; Chattergoon M A; Dang K; Wang B; Boyer J D; Weiner D B
TI In vivo engineering of a cellular **immune response** by coadministration of **IL-12** expression vector with a **DNA** immunogen.
SO Journal of immunology (Baltimore, Md. : 1950), (1997 Jan 15) 158 (2) 816-26.
Journal code: 2985117R. ISSN: 0022-1767.

L13 ANSWER 28 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Houssiau F A (Reprint); MascartLemone F; Stevens M; Libin M; Devogelaer J P; Goldman M; Renauld J C
TI IL-12 inhibits in vitro immunoglobulin production by human lupus peripheral blood mononuclear cells (PBMC)
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (MAY 1997) Vol. 108, No. 2, pp. 375-380.
Publisher: BLACKWELL SCIENCE LTD, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL.
ISSN: 0009-9104.

=> d au ti so pi 1-28 l16

L16 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
IN Kent, Stephen John
TI Same antigen-derived peptide set and antigen-presenting cells or precursors for modulating immune response against cancer, infection, autoimmune disease and allergy
SO PCT Int. Appl., 645 pp.
CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004108753	A1	20041216	WO 2004-AU775	20040610

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L16 ANSWER 2 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Gilleron, Martine; Stenger, Steffen; Mazorra, Zaima; Wittke, Frederick; Mariotti, Sabrina; Bohmer, Gabriele; Prandi, Jacques; Mori, Lucia; Puzo, Germain; De Libero, Gennaro [Reprint Author]
TI Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis.
SO Journal of Experimental Medicine, (March 1 2004) Vol. 199, No. 5, pp. 649-659. print.
ISSN: 0022-1007 (ISSN print).

L16 ANSWER 3 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Joharapurkar, A. A.; Zambad, S. P.; Wanjari, M. M.; Umathe, S. N. [Reprint Author]
TI In vivo evaluation of antioxidant activity of alcoholic extract of Rubia cordifolia Linn. and its influence on ethanol-induced immunosuppression.
SO Indian Journal of Pharmacology, (August 2003) Vol. 35, No. 4, pp. 232-236. print.
ISSN: 0253-7613 (ISSN print).

L16 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
IN Sette, Alessandro; Sidney, John; Southwood, Scott; Vitiello, Maria A.; Livingstone, Brian D.; Celis, Esteban; Kubo, Ralph T.; Grey, Howard M.; Chesnut, Robert W.
TI Epitope-based vaccine compositions for inducing cellular immune responses against hepatitis B virus
SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002019986	A1	20020314	WO 2000-US24802	20000908
WO 2002019986	C2	20020801		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2422506	AA	20020314	CA 2000-2422506	20000908
AU 2000078281	A5	20020322	AU 2000-78281	20000908
EP 1322288	A1	20030702	EP 2000-968348	20000908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000017332	A	20031007	BR 2000-17332	20000908
JP 2004508320	T2	20040318	JP 2002-524471	20000908

L16 ANSWER 5 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Sweet C R; Preston A; Toland E; Ramirez S M; Cotter R J; Maskell D J; Raetz C R H (Reprint)
TI Relaxed acyl chain specificity of Bordetella UDP-N-acetylglucosamine acyltransferases

SO JOURNAL OF BIOLOGICAL CHEMISTRY, (24 MAY 2002) Vol. 277, No. 21, pp. 18281-18290.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA.
ISSN: 0021-9258.

L16 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
IN Sette, Alessandro; Sidney, John; Southwood, Scott; Livingston, Brian D.; Chesnut, Robert; Baker, Denise Marie; Celis, Esteban; Kubo, Ralph T.; Grey, Howard M.
TI Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
SO PCT Int. Appl., 448 pp.
CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001024810	A1	20010412	WO 2000-US27766	20001005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2386499	AA	20010412	CA 2000-2386499	20001005
EP 1225907	A1	20020731	EP 2000-972031	20001005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003510099	T2	20030318	JP 2001-527809	20001005

L16 ANSWER 7 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Dubreuil C
TI Inflammation and acute middle-ear otitis: the 10 key points
SO PRESSE MEDICALE, (22 DEC 2001) Vol. 30, No. 39-40, Part 2, pp. 19-25.
Publisher: MASSON EDITEUR, 120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE.
ISSN: 0755-4982.

L16 ANSWER 8 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU Cummings R D (Reprint); Nyame A K
TI Schistosome glycoconjugates
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, (8 OCT 1999) Vol. 1455, No. 2-3, pp. 363-374.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
ISSN: 0925-4439.

L16 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Polyakov, L. M.; Panin, L. E.
TI Apolipoprotein E: structure and function
SO Uspekhi Sovremennoi Biologii (1998), 118(6), 743-753
CODEN: USBIA3; ISSN: 0042-1324

L16 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
IN Snapper, Clifford M.; Mond, James J.; Capiau, Carine; Hauser, Pierre; Prieels, Jean-Paul
TI Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9632963	A1	19961024	WO 1996-US5226	19960416
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	CA 2218385	AA	19961024	CA 1996-2218385	19960416
	AU 9654856	A1	19961107	AU 1996-54856	19960416
	AU 716806	B2	20000309		
	ZA 9603001	A	19980116	ZA 1996-3001	19960416
	EP 824360	A1	19980225	EP 1996-911776	19960416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11508225	T2	19990721	JP 1996-531844	19960416
	NZ 306316	A	20010629	NZ 1996-306316	19960416

L16 ANSWER 11 OF 28 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU HAWKEY C J (Reprint); MAHIDA Y R; HAWTHORNE A B
TI THERAPEUTIC INTERVENTIONS IN GASTROINTESTINAL-DISEASE BASED ON AN UNDERSTANDING OF INFLAMMATORY MEDIATORS
SO AGENTS AND ACTIONS, (1992) Sp. iss. SI, pp. C22-C26.
ISSN: 0065-4299.

L16 ANSWER 12 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU TOMITA-YAMAGUCHI M [Reprint author]; RUBIO C; SANTORO T J
TI REGIONAL INFLUENCES ON THE PHYSICAL PROPERTIES OF T CELL MEMBRANES.
SO Life Sciences, (1991) Vol. 48, No. 5, pp. 433-438.
CODEN: LIFSAK. ISSN: 0024-3205.

L16 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Wick, Georg; Huber, Lukas A.; Xu, Qing Bo; Jarosch, Elmar; Schoenitzer, Diether; Juergens, Guenther
TI The decline of the immune response during aging: the role of an altered lipid metabolism
SO Annals of the New York Academy of Sciences (1991), 621(Physiol. Senescence Its Postponement: Theor. Approaches Ration. Interventions), 277-90
CODEN: ANYAA9; ISSN: 0077-8923

L16 ANSWER 14 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU APICELLA M A [Reprint author]
TI NEISSERIA-MENINGITIDIS.
SO (1990) pp. 1600-1613. MANDELL, G. L., R. G. DOUGLAS, JR. AND J. E. BENNETT (ED.). PRINCIPLES AND PRACTICE OF INFECTIOUS DISEASES, THIRD EDITION. XXIX+2340P. CHURCHILL LIVINGSTONE INC.: NEW YORK, NEW YORK, USA; EDINBURGH, SCOTLAND, UK. ILLUS. MAPS.
ISBN: 0-443-08686-9.

L16 ANSWER 15 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU ZENITA K [Reprint author]; HIRASHIMA K; SHIGETA K; HIRAIWA N; TAKADA A; HASHIMOTO K; FUJIMOTO E; YAGO K; KANNAGI R
TI NORTHERN HYBRIDIZATION ANALYSIS OF V-H GENE EXPRESSION IN MURINE MONOCLONAL ANTIBODIES DIRECTED TO CANCER-ASSOCIATED GANGLIOSIDE ANTIGENS HAVING VARIOUS SIALIC ACID LINKAGES.
SO Journal of Immunology, (1990) Vol. 144, No. 11, pp. 4442-4451.
CODEN: JOIMA3. ISSN: 0022-1767.

L16 ANSWER 16 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

AU HARN D A [Reprint author]; CIANCI C M L; CAULFIELD J P
TI SCHISTOSOMA-MANSONI IMMUNIZATION WITH CERCARIAL GLYCOCALYX PREPARATION INCREASES THE ADULT WORM BURDEN.
SO Experimental Parasitology, (1989) Vol. 68, No. 1, pp. 108-110.
CODEN: EXPAAA. ISSN: 0014-4894.

L16 ANSWER 17 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU RIVICH D A [Reprint author]; ROSEN G M; COHEN H J
TI MEMBRANE PROTEIN ORGANIZATION OF PERIPHERAL BLOOD LYMPHOCYTES FROM HEALTHY YOUNG AND AGED ADULTS.
SO Mechanisms of Ageing and Development, (1988) Vol. 45, No. 1, pp. 65-74.
CODEN: MAGDA3. ISSN: 0047-6374.

L16 ANSWER 18 OF 28 MEDLINE on STN DUPLICATE 2
AU Baisheva S A; Zhalgasbaeva G T; Sysoeva M I; Asanov A A; Dil'man V M
TI [Immunocorrective therapy in esophageal cancer].
Immunokorrigiruiushchaia terapiia pri rake pishchevoda.
SO Voprosy onkologii, (1987) 33 (7) 38-43.
Journal code: 0413775. ISSN: 0507-3758.

L16 ANSWER 19 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU PIERRUGUES R [Reprint author]; BAURET P; MICHEL H
TI CONTINUOUS ENTERAL NUTRITION IN DENUTRITIVE ALCOHOLIC CIRRHOTICS RANDOMIZED TRIAL.
SO Journal of Hepatology, (1985) No. SUPPL. 2, pp. S308.
Meeting Info.: 20TH MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER, ESPOO, FINLAND, AUG. 29-31, 1985. J HEPATOL (AMST).
CODEN: JOHEEC. ISSN: 0168-8278.

L16 ANSWER 20 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU NAGORNEV V A [Reprint author]; PIGAREVSKII P V; OGURTSOV R P; DENISENKO A D
TI ATHEROSCLEROSIS AND THE IMMUNITY SYSTEM.
SO Arkhiv Patologii, (1985) Vol. 47, No. 4, pp. 15-21.
CODEN: ARPTAF. ISSN: 0004-1955.

L16 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Hoffeld, J. Terrell
TI Agents which block membrane lipid peroxidation enhance mouse spleen cell immune activities in vitro: relationship to the enhancing activity of 2-mercaptoethanol
SO European Journal of Immunology (1981), 11(5), 371-6
CODEN: EJIMAF; ISSN: 0014-2980

L16 ANSWER 22 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AU MICHEL B [Reprint author]; GUILHOU J-J; CRASTES DE PAULET A; MEYNADIER J; CHANTREUIL J
TI PROSTAGLANDIN BIOSYNTHESIS IN PSORIATIC EPIDERMIS.
SO Annales de Dermatologie et de Venereologie, (1980) Vol. 107, No. 10, pp. 889-893.
ISSN: 0151-9638.

L16 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Shine, Thomas E.; Little, J. Russell; Shore, Virgie; Medoff, Gerald; Abegg, Ann
TI Effect of exogenous lipids and lipoproteins on the primary immune response in vitro
SO European Journal of Immunology (1980), 10(9), 714-18
CODEN: EJIMAF; ISSN: 0014-2980

L16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Suh, Neba Ngwa; Ebringer, Alan
TI Genetic control of the immune response to bacteriophage .vphi.X174 in inbred mice
SO Biochemical Society Transactions (1978), 6(5), 1065-7
CODEN: BCSTB5; ISSN: 0300-5127

L16 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Horikoshi, Michiko; Kamijo, Kiyoaki
TI Phage protein. VI. Immune response of the three fractions of P22 phage coat protein. 2
SO Juntendo Igaku (1972), 18(1), 100-5
CODEN: JUIZAG; ISSN: 0022-6769

L16 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Koelsch, E.; Diller, Eva; Weber, G.; Davies, A. J. S.
TI Genetics of the immune response. I. Immune response to the phage fd in high and low responding inbred strains of mice
SO European Journal of Immunology (1971), 1(3), 201-10
CODEN: EJIMAF; ISSN: 0014-2980

L16 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Panijel, J.; Delamette, Francoise; Leneveu, Micheline
TI Cellular and subcellular study of the in vitro immune response
SO European Journal of Immunology (1971), 1(2), 87-97
CODEN: EJIMAF; ISSN: 0014-2980

L16 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
AU Smith, James William; Barnett, Jack A.; Sanford, Jay P.
TI Heterogeneity of immune response to the somatic (O) antigens of Proteus mirabilis
SO Journal of Immunology (1970), 105(2), 404-10
CODEN: JOIMA3; ISSN: 0022-1767